A Cryoprotectant‐Compatible Nanoporous Platform for Stable and Scalable Delivery of Biopharmaceuticals
Advanced Materials · 2026-06 · 38 (33)
DOI: 10.1002/adma.202510532 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 12.03.2026. Verfasst von Sian Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Biomaterial Research Center, Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Cryoprotective Agents, Nanopores. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation of Korea, Korea Health Industry Development Institute, Ministry of Health & Welfare, Republic of Korea, KIST Institutional Program.
Abstract (Originalsprache)
CRISPR‐Cas9 ribonucleoproteins (RNPs) represent a promising class of biopharmaceuticals for treating genetic and complex diseases. However, their clinical translation is limited by instability during storage and delivery. Lyophilization offers a potential solution, though conventional approaches often compromise structural integrity and bioactivity under non‐cryogenic conditions. Here, we have developed a nanostructured delivery platform, designated Nano Banker & Blowball (NB 2 ), which features a blowball‐like architecture and tunable nanoscale pores. These pores are designed to protect RNPs and enable controlled release. The freeze‐dried formulation (FNB 2 ) integrates optimized cryoprotectants and a surface‐engineered nanoparticle design, preserving morphology and function without excessive excipients. FNB 2 exhibits rapid rehydration and retains ∼70% of gene editing activity post‐lyophilization, enabling robust functional gene editing in vitro and in vivo. It also maintains long‐term stability and supports efficient cellular uptake, enabling administration via multiple routes. FNB 2 represents a scalable and robust platform for genetic therapeutics, vaccines, and biologics, particularly well‐suited for resource‐limited and emergency medical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomaterial Research Center, Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
- School of Biomedical Engineering, Korea University, Seoul, Republic of Korea.
- College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju, Gyeongsangnam-do, Republic of Korea.
- Department of Chemistry, Seoul National University, Seoul, Republic of Korea.
- Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
- Division of Bio-Medical Science &Technology, KIST School, University of Science and Technology, Seoul, Republic of Korea.
ORCID-Profile: Hyojin Lee
Förderung
- National Research Foundation of Korea
- Korea Health Industry Development Institute, Ministry of Health & Welfare, Republic of Korea
- KIST Institutional Program
Zitieren
APA
Lee, S., Kim, S., Chong, J., Kim, M. G., Lim, K., Lee, N. E., Koo, J., Kang, J., & Lee, H. (2026). A Cryoprotectant‐Compatible Nanoporous Platform for Stable and Scalable Delivery of Biopharmaceuticals. Advanced Materials, 38(33). https://doi.org/10.1002/adma.202510532
Vancouver
Lee S, Kim S, Chong J, Kim MG, Lim K, Lee NE, et al. A Cryoprotectant‐Compatible Nanoporous Platform for Stable and Scalable Delivery of Biopharmaceuticals. Advanced Materials. 2026;38(33). doi:10.1002/adma.202510532
BibTeX
@article{Lee2026,
author = {Lee, Sian and Kim, Seongchan and Chong, Jooyeun and Kim, Min-Gyeong and Lim, Kayeong and Lee, Nan-Ee and Koo, Jahyun and Kang, Jiheong and Lee, Hyojin},
title = {A Cryoprotectant‐Compatible Nanoporous Platform for Stable and Scalable Delivery of Biopharmaceuticals},
journal = {Advanced Materials},
year = {2026},
volume = {38},
number = {33},
doi = {10.1002/adma.202510532}
}
EUVIMED